Neobiomics AB and ExCEEd Orphan s.r.o. announce exclusive cooperation for Central and Eastern Europe

Press Release in PDF format.
Stockholm, Sweden, 21 May, 2021 – Neobiomics AB and ExCEEd Orphan s.r.o. have entered an exclusive distribution agreement valid for 14 countries in Central and Eastern Europe (CEE). The agreement includes marketing and sales of Neobiomics’ proprietary product ProPrems® and is in effect immediately. 

Neobiomics is a Sweden-based company specialized in the area of neonatal and child health care and ExCEEd Orphan s.r.o. is a Czech Republic-based company focused on products for the treatment of rare diseases.  

Dr. Stefan Johansson, CEO and Founder of Neobiomics, regards the agreement as another important step for ProPrems® market expansion: “We at Neobiomics are very excited to work with ExCEEd Orphan. Their expertise and knowledge of marketing and sales in the CEE region will enable a quick uptake of ProPrems®. It is great to collaborate with such an enthusiastic and experienced team in this important territory.” 

Jiri Hermanek, CEO and Founding Partner of ExCEEd Orphan comments: “ProPrems®, Neobiomics’ high-quality multi-strain food supplement for premature newborns, is a natural fit for our portfolio in the CEE countries. We are looking forward working with Neobiomics to bring this science-based product to patients in need in CEE countries.” 

About Neobiomics 

Neobiomics AB, founded in 2016 by Stefan Johansson and Philipp Novak, is an alumni member of the Innovation Incubator at Karolinska Institutet Innovation AB. The first product ProPrems® is a high-quality multi-strain food supplement manufactured by Chr. Hansen, a world-wide leader in manufacturing bacterial cultures. ProPrems® is now available in a majority of European countries and continues its geographical expansion within Europe.  

About  ExCEEd Orphan s.r.o. 

ExCEEd Orphan s.r.o. was founded in 2018 by 5 rare disease experts from multiple CEE countries. The company is focusing on innovative treatments for rare diseases and has extensive experience in launching innovative medicines in this field.  The portfolio of ExCEEd Orphan includes products in therapeutic areas like hematology, neurology, immunology, and metabolic diseases. 

For further information, please refer to www.neobiomics.eu and www.exceedorphan.com